Skip to main content
. 2018 Mar 21;10(4):88. doi: 10.3390/cancers10040088

Table 2.

Description of the mutational status of the 90 patients with advanced non-small cell lung cancer included in the study.

Mutation Status Retrospective Cohort [N = 60] Prospective Cohort [N = 30]
No detected mutations 25 (42%) 5 (17%)
Mutations detected in 33 (55%) 25 (83%)
EGFR 9 (15%) 8 (27%)
KRAS 20 (33%) 13 (43%)
BRAF 3 (5%) 2 (7%)
Double Mutations
EGFR del19 & KRAS p.G12D 1 (2%) na
EGFR p.V774M & p.L861Q na 1 (3%)
EGFR p.L858R & p.G719C na 1 (3%)
Failed analysis 2 (3%) na